Lilly Wows ADA Crowd With Obesity Data Across Three-Drug Incretin Portfolio
Weight Loss Of Up To 24.2% With ‘Triple G’ Retatrutide
Lilly may gain its first US approval in obesity with Mounjaro before the end of 2023, but presented data at ADA for it and two other drugs – retatrutide and orforglipron – that also yielded significant weight loss.
